MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

13.13 -1.13

Buy Sell

Overview

Share price change

24h

Current

Min

12.81

Max

13.2

Key metrics
By Trading Economics
Income	222M 227M
Sales	-23M 139M
P/E Sector Avg	5.057 78.892
Profit margin	163.843
Employees	1,780
EBITDA	6.3M 1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+86.57% upside

Market Stats
By TradingEconomics
Market Cap	-373M 2.3B
Previous open	14.26
Previous close	13.13

News Sentiment

By Acuity

50%

151 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 gru 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

WiseTech to Sell Expedient to Appease Competition Regulator

30 gru 2025, 17:12 UTC

Major Market Movers

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 gru 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30 gru 2025, 21:08 UTC

Market Talk

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30 gru 2025, 20:41 UTC

Market Talk

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30 gru 2025, 20:37 UTC

Earnings

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30 gru 2025, 19:29 UTC

Market Talk

Corn Extends Pullback in Light Trade -- Market Talk

30 gru 2025, 18:29 UTC

Market Talk

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 gru 2025, 16:20 UTC

Earnings

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30 gru 2025, 16:10 UTC

Market Talk

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30 gru 2025, 15:24 UTC

Market Talk

Australian Dollar Could Rise Versus Sterling -- Market Talk

30 gru 2025, 15:10 UTC

Acquisitions, Mergers, Takeovers

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30 gru 2025, 14:24 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30 gru 2025, 14:22 UTC

Acquisitions, Mergers, Takeovers

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30 gru 2025, 14:20 UTC

Acquisitions, Mergers, Takeovers

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30 gru 2025, 14:17 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30 gru 2025, 14:16 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30 gru 2025, 14:14 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30 gru 2025, 14:12 UTC

Acquisitions, Mergers, Takeovers

LVMH: Les Editions Croque Futur Is a French Publishing House

30 gru 2025, 14:10 UTC

Acquisitions, Mergers, Takeovers

LVMH Acquires Les Editions Croque Futur

30 gru 2025, 13:49 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30 gru 2025, 13:36 UTC

Market Talk

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30 gru 2025, 13:30 UTC

Market Talk

Crude Futures Gain in Light Holiday Trade -- Market Talk

30 gru 2025, 12:55 UTC

Market Talk

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30 gru 2025, 11:55 UTC

Market Talk

Earnings

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30 gru 2025, 11:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30 gru 2025, 11:35 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

86.57% upside

12 Months Forecast

Average 25 USD 86.57%

High 25 USD

Low 25 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

151 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.